Compare PRK & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRK | IDYA |
|---|---|---|
| Founded | 1908 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.6B |
| IPO Year | 1996 | 2019 |
| Metric | PRK | IDYA |
|---|---|---|
| Price | $191.67 | $39.98 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 16 |
| Target Price | ★ $184.00 | $52.86 |
| AVG Volume (30 Days) | 67.5K | ★ 701.7K |
| Earning Date | 04-24-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.61% | N/A |
| EPS Growth | 19.21 | ★ 61.90 |
| EPS | ★ 5.64 | N/A |
| Revenue | ★ $664,421,000.00 | $218,710,000.00 |
| Revenue This Year | $24.26 | N/A |
| Revenue Next Year | $3.63 | $201.05 |
| P/E Ratio | $34.63 | ★ N/A |
| Revenue Growth | 2.92 | ★ 3024.43 |
| 52 Week Low | $149.06 | $23.23 |
| 52 Week High | $215.00 | $42.68 |
| Indicator | PRK | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 36.60 | 58.13 |
| Support Level | $181.01 | $33.57 |
| Resistance Level | $192.77 | $39.93 |
| Average True Range (ATR) | 4.14 | 1.35 |
| MACD | -1.97 | 0.09 |
| Stochastic Oscillator | 8.62 | 59.26 |
Park National Corp is a diversified financial services company based in Newark, Ohio, consisting of 11 community banking divisions with more than 100 offices in Ohio and Kentucky. The company provides the following principal services: the acceptance of deposits for demand, savings and time accounts; commercial, industrial, consumer and real estate lending, including installment loans, credit cards (which are largely offered through a third party), home equity lines of credit and commercial leasing; trust and wealth management services; cash management; safe deposit operations; electronic funds transfers; and a variety of additional banking-related services.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.